Revenue ($USD) : $447,605,000
R&D spend : $57,129,000
Employees : 1,024
Fiscal year end : 6/30/2023
CEO : Suzanne Winter

www.accuray.com

Accuray specializes in radiation therapy systems to deliver treatments including stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). The company closed out 2023 with a 6% workforce reduction as part of a margin expansion plan. It picked up a big regulatory win in June 2024 as Chinese authorities approved its Precision treatment planning system (TPS), expanding access to care for cancer patients in China. –SW and JH